Effect of Prolonged Use of Dronedarone on Recurrence in Patients With Non-paroxysmal Atrial Fibri… (NCT05655468) | Clinical Trial Compass
UnknownPhase 4
Effect of Prolonged Use of Dronedarone on Recurrence in Patients With Non-paroxysmal Atrial Fibrillation After Radiofrequency Ablation
China268 participantsStarted 2023-03-29
Plain-language summary
Recurrence rate remains high after radiofrequency ablation in patients with non-paroxysmal atrial fibrillation(AF). Prolonged use of anti-arrhythmic drugs (AAD) beyond the post-ablation blanking has been adopted as a solution but without sufficient clinical evidence. Dronedarone is an AAD valid to maintain sinus rhythm and has fewer side effect than other AAD for long-term use.We sought to investigate the effect of prolonged use of dronedarone on recurrence of non-paroxysmal AF patients beyond the post-blanking period within the first year after ablation.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged 18-80 years;
✓. Diagnosis of non-paroxysmal AF
✓. Undergoing AF ablation for the first time
Exclusion criteria
✕. Unwilling to take or intolerant to dronedarone;
✕. Hypersensitivity to the drug ingredient
✕. Patients with decompensated heart failure, class NYHA IV, or left ventricular ejection fraction (LVEF) ≤40%
✕. Bradycardia \<50 bpm
✕. QTc Bazett interval ≥500ms or PR interval \>280ms
✕. II or III atrioventricular (AV) block or sick-sinus syndrome without permanent pacemaker
✕. Diagnosed with acute coronary syndrome or treated with percutaneous coronary intervention within the last 3 months